2015
DOI: 10.1111/ajt.13181
|View full text |Cite
|
Sign up to set email alerts
|

Evaluation of the Effect of Tofacitinib Exposure on Outcomes in Kidney Transplant Patients

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
35
0

Year Published

2016
2016
2024
2024

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 53 publications
(36 citation statements)
references
References 23 publications
1
35
0
Order By: Relevance
“…Tofacitinib was first studied in the prevention of transplant rejection 104,105 , where it was efficacious but was also associated with an unacceptable risk of adverse events due to over-immunosuppression. Foremost among these were BK viremia, nephropathy, and post-transplant lymphoproliferative disease (PTLD).…”
Section: Other Autoimmune and Autoinflammatory Diseasesmentioning
confidence: 99%
“…Tofacitinib was first studied in the prevention of transplant rejection 104,105 , where it was efficacious but was also associated with an unacceptable risk of adverse events due to over-immunosuppression. Foremost among these were BK viremia, nephropathy, and post-transplant lymphoproliferative disease (PTLD).…”
Section: Other Autoimmune and Autoinflammatory Diseasesmentioning
confidence: 99%
“…Univariate analysis showed that tofacitinib exposure, as measured by C 0 and C 2 , donor and recipient age, and use of CMV prophylaxis were associated with occurrence of serious infection. 26 Using multiple regression analysis, only tofacitinib C 2 concentrations were independently associated with serious infection (C 0 was not entered into the multiple regression analysis). Interestingly, MPA C 0 concentrations were not associated with serious infections.…”
Section: Experience With Jak3 Inhibitors In Kidney Transplant Patientsmentioning
confidence: 99%
“…These data suggest that monitoring of plasma concentrations of tofacitinib may preserve the overall benefits including low rates of acute rejection, improved renal function, and a lower incidence of interstitial fibrosis and tubular atrophy with similar rates of serious infection and no PTLD. 26 …”
Section: Experience With Jak3 Inhibitors In Kidney Transplant Patientsmentioning
confidence: 99%
See 1 more Smart Citation
“…An interesting finding of this trial was that safety was based on tofacitinib exposure, measured as time-weighted 2 hour postdose concentrations. 56 Patients were categorized to above-median (AME) or below-median (BME) exposure. While both AME and BME provided low rejection rates, serious infections occurred more frequently in AME patients and all 5 cases of posttransplant lymphoproliferative disease (PTLD) were in this high exposure group.…”
Section: Tofacitinib: a Promising Drug Victim Of The Marketplacementioning
confidence: 99%